Natural compound Byakangelicin suppresses breast tumor growth and motility by regulating SHP-1/JAK2/STAT3 signal pathway
Authors:
- 5 March 2024
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 706, 149758
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Shanghai Municipal Health Commission
This publication has 24 references indexed in Scilit:
- Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signalingBiomedicine & Pharmacotherapy, 2022
- STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy responsePharmacological Research, 2022
- 3-Deoxy-2β,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cellsActa Pharmacologica Sinica, 2019
- EMT Transition States during Tumor Progression and MetastasisTrends in Cell Biology, 2019
- Targeting the IL-6/JAK/STAT3 signalling axis in cancerNature Reviews Clinical Oncology, 2018
- Revisiting STAT3 signalling in cancer: new and unexpected biological functionsNature Reviews Cancer, 2014
- Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathwayBreast Cancer Research and Treatment, 2014
- Anti-tumor effects of various furocoumarins isolated from the roots, seeds and fruits of Angelica and Cnidium species under ultraviolet A irradiationJournal of Natural Medicines, 2013
- Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast CancerJournal of Mammary Gland Biology and Neoplasia, 2010
- Jak family of kinases in cancerCancer and Metastasis Reviews, 2003